Can a Daily GLP-1 Pill Replace Weekly Injections? The ATTAIN-MAINTAIN Trial Says Yes

If you've been losing weight on a weekly GLP-1 injection but wondering whether you'll need to keep injecting forever, there's encouraging news. The ATTAIN-MAINTAIN trial — published May 12, 2026 in Nature Medicine — showed that switching to a daily oral GLP-1 pill helped patients maintain the vast majority of their weight loss and cardiometabolic improvements.

What the Study Found

The trial enrolled patients who had already achieved substantial, plateaued weight loss while taking injectable GLP-1s in the SURMOUNT-5 trial (which compared tirzepatide vs. semaglutide head-to-head). Those patients were then switched to orforglipron, a once-daily oral GLP-1 pill made by Eli Lilly.

The results were clinically meaningful:

• Patients maintained approximately 75–80% of their weight loss after switching to the pill
• Health improvements were preserved — including reduced waist circumference, blood pressure, blood sugar, triglycerides, and cholesterol levels
• Side effects were mild to moderate, predominantly gastrointestinal (consistent with all GLP-1 medications)
• The oral medication was generally well tolerated

An Important Nuance: Semaglutide Switchers vs. Tirzepatide Switchers

The researchers found an interesting pattern when comparing patients based on what they'd been injecting before the switch:

Patients who switched from semaglutide (Wegovy/Ozempic) to orforglipron maintained weight loss better. This makes biological sense — semaglutide and orforglipron both target a single receptor (GLP-1), so the transition is mechanistically smoother.

Patients who switched from tirzepatide (Zepbound/Mounjaro) saw somewhat more weight regain. Tirzepatide targets two receptors (GLP-1 and GIP), producing greater initial weight loss. Switching to a single-target oral drug means some of that dual-target benefit is lost.

Why This Matters for You

This study addresses one of the biggest practical concerns about GLP-1 treatment: the long-term logistics. Many patients don't want to inject themselves weekly forever. Some have difficulty with injection anxiety, traveling with refrigerated medication, or simply prefer the convenience of a pill.

The ATTAIN-MAINTAIN data suggests a practical treatment pathway: use injectable GLP-1s during the active weight loss phase (when maximum efficacy matters most), then transition to an oral pill for long-term maintenance. You might not maintain 100% of the loss, but keeping 75–80% is a strong clinical outcome.

When Can You Actually Do This?

Orforglipron (brand name: Foundayo) is expected to receive FDA approval by the end of June 2026. Once approved, it would be available by prescription. Key advantages over the existing Wegovy pill: orforglipron can be taken at any time of day, with or without food. The Wegovy pill requires an empty stomach and a 30-minute wait.

What This Doesn't Tell Us

A few important caveats:

• The study was sponsored by Eli Lilly, which manufactures both orforglipron and tirzepatide. Dr. Aronne is a paid consultant for the company.
• Dual-acting oral GLP-1s (targeting both GLP-1 and GIP) aren't yet available — when they arrive, the maintenance picture may improve further for patients coming off tirzepatide.
• The study doesn't tell us what happens if you stop the oral pill entirely. Based on other research, weight regain would be expected.

Still, this is the first rigorous evidence that an injectable-to-oral transition can work. For the millions of Americans currently on GLP-1 injections who are thinking about their long-term treatment plan, it's genuinely good news.